Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Triple Negative Breast Neoplasms 1Thoracic Neoplasms 1Small Cell Lung Carcinoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1

Interventions

Dexamethasone 124Lenalidomide 76daratumumab 69Bortezomib 57pomalidomide 45carfilzomib 44Cyclophosphamide 40Calcium Dobesilate 36Specimen Handling 31Biopsy 29Magnetic Resonance Spectroscopy 26belantamab mafodotin 22isatuximab 20fludarabine 20talquetamab 19iberdomide 17dexamethasone acetate 14dexamethasone 21-phosphate 14auricularum 14Melphalan 14fludarabine phosphate 13elotuzumab 12tocilizumab 9selinexor 9X-Rays 8Nivolumab 8trametinib 7Whole-Body Irradiation 7Sirolimus 7Mycophenolic Acid 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Multiple Myeloma × efineptakin alfa × 90 days × Clear all
NCT07200089 2026-04-07

Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)

Washington University School of Medicine

Phase 1 Not yet recruiting
52 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡